- Home
- CRVS vs GEVO Comparison
CRVS vs GEVO Comparison
Compare CRVS & GEVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- GEVO
- Stock Information
- Founded
- CRVS 2014
- GEVO 2005
- Country
- CRVS United States
- GEVO United States
- Employees
- CRVS N/A
- GEVO N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- GEVO Major Chemicals
- Sector
- CRVS Health Care
- GEVO Industrials
- Exchange
- CRVS Nasdaq
- GEVO Nasdaq
- Market Cap
- CRVS 459.0M
- GEVO 418.4M
- IPO Year
- CRVS 2016
- GEVO 2011
- Fundamental
- Price
- CRVS $5.83
- GEVO $1.67
- Analyst Decision
- CRVS Strong Buy
- GEVO Buy
- Analyst Count
- CRVS 4
- GEVO 2
- Target Price
- CRVS $15.00
- GEVO $7.58
- AVG Volume (30 Days)
- CRVS 596.4K
- GEVO 3.7M
- Earning Date
- CRVS 11-11-2025
- GEVO 11-06-2025
- Dividend Yield
- CRVS N/A
- GEVO N/A
- EPS Growth
- CRVS N/A
- GEVO N/A
- EPS
- CRVS N/A
- GEVO N/A
- Revenue
- CRVS N/A
- GEVO $80,187,000.00
- Revenue This Year
- CRVS N/A
- GEVO $909.99
- Revenue Next Year
- CRVS N/A
- GEVO $22.37
- P/E Ratio
- CRVS N/A
- GEVO N/A
- Revenue Growth
- CRVS N/A
- GEVO 341.75
- 52 Week Low
- CRVS $2.54
- GEVO $0.76
- 52 Week High
- CRVS $10.00
- GEVO $3.39
- Technical
- Relative Strength Index (RSI)
- CRVS 58.56
- GEVO 53.85
- Support Level
- CRVS $5.90
- GEVO $1.59
- Resistance Level
- CRVS $6.30
- GEVO $1.73
- Average True Range (ATR)
- CRVS 0.32
- GEVO 0.09
- MACD
- CRVS -0.00
- GEVO -0.02
- Stochastic Oscillator
- CRVS 53.92
- GEVO 34.48
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About GEVO Gevo Inc.
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.